按下ENTER到主內容區
:::

Investors Optimistic as Oral Weight-Loss Drugs Could Expand Global Market

Oral weight loss drugs lift pharma shares(Photo envato/africaimages)
Oral weight loss drugs lift pharma shares(Photo envato/africaimages)

Shares of Novo Nordisk and Eli Lilly rose this week as investors reacted positively to signs that oral weight-loss drugs could significantly expand the global obesity treatment market.

Currently, many of the most popular weight-loss medications - including Novo Nordisk's Wegovy and Eli Lilly's Zepbound - are administered through injections. However, pharmaceutical companies are increasingly developing pill-based alternatives to make treatment more convenient and accessible.

According to Reuters, analysts believe oral weight-loss drugs could attract a broader group of patients, especially those unwilling to use injectable medications for long-term weight management.

The growing demand for obesity treatment is driven by rising global rates of obesity and metabolic diseases. Industry experts say future competition will depend not only on effectiveness, but also on pricing, insurance coverage, convenience, and side effect management.

Medical professionals also caution that weight-loss medications should not be viewed as quick-fix solutions. Long-term success still depends on lifestyle changes such as diet, exercise, and ongoing medical supervision.

Popular News

回到頁首
Loading